BeiGene Inks $1.8B Deal for MAT2A Inhibitor; HealthyWay Clears HKEX Listing Hearing

$1.8 Billion! BeOne Medicines Makes a Major Investment in a Promising Pipeline

On December 13, BeOne Medicines announced that it had entered into an exclusive licensing agreement with CSPC regarding the global development, manufacturing, and commercialization of a novel methionine adenosyltransferase 2A (MAT2A) inhibitor (SYH2039), as well as any pharmaceutical products containing or composed of this compound developed subsequently (related products). Under the terms and conditions of the agreement, CSPC has agreed to grant BeOne Medicines the exclusive rights to develop, manufacture, and commercialize SYH2039 and related products globally. (Source: Medical Investment)

Autobio Diagnostics Co., Ltd. and Shanghai Pharmaceuticals Supply Chain Reach Strategic Cooperation

Recently, Autobio Diagnostics Co., Ltd. ("Autobio") and Shanghai Pharmaceuticals Supply Chain Management (Shanghai) Co., Ltd. ("SPH Supply Chain") held a strategic cooperation agreement signing ceremony at Autobio's in vitro diagnostics industrial park. Mr. Yang Zengli, General Manager of Autobio, and Mr. Xue Ning, General Manager of SPH Supply Chain, jointly signed the strategic cooperation agreement. The signing of this agreement marks a new phase in the collaboration between Autobio and SPH Supply Chain. In the future, both parties will continue to deepen their strategic partnership, strengthen cooperation in procurement and distribution of in vitro diagnostic products and services, enhance communication, share market information and resources, and provide strong support for each other’s development. (Source: Arterial Network)

Fujian Health Road Information Technology Co., Ltd. Passes Listing Hearing

Another listed company is about to join the internet healthcare sector! According to information disclosed on the Hong Kong Stock Exchange, Health Road has passed the listing hearing. Since its establishment in 2001, Health Road has expanded its service boundaries from online appointment scheduling and now built two major business segments: health medical services for C-end users and enterprise services and digital marketing services for B-end clients (including hospitals). Throughout the development of internet healthcare, Health Road has repeatedly hit key milestones, achieving steady growth and rapid performance increases in recent years. From 2021 to 2023, Health Road's annual revenue surged from 431 million yuan to 1.244 billion yuan; total revenue in the first half of 2024 reached 611 million yuan, a year-on-year increase of 14.5%. In terms of adjusted net profit, Health Road has remained profitable over the past three years. (Source: Vbdata.cn)

Grand Pharmaceutical Group Limited BD+1

On December 11, Grand Pharmaceutical Group Limited announced that it had recently reached a product introduction strategic cooperation agreement with CORXEL (Hong Kong) Limited ("CORXEL"). According to the agreement, upon fulfillment of relevant conditions, the company will obtain exclusive development and commercialization rights for the world's first innovative products for the treatment of dry eye disease, Varenicline Tartrate Nasal Spray (“OC-01”) and Simpinicline Nasal Spray (“OC-02”), in Greater China (Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan region). (Source: Arterial Network)

Bochuang Biotech Completes Pre-A Round of Tens of Millions of Yuan in Financing

Recently, Bochuang Biotech (hereinafter referred to as "Bochuang Bio") successfully completed a Pre-A round of financing worth tens of millions of yuan. This round of financing involved several well-known investment institutions. It was led by Hangzhou Huafang Capital, with participation from Taiyu Investment, Bangming Capital, and Suzhou Industrial Park Leading Venture Capital. This marks Bochuang Bio's third round of financing in the past two years. (Source: Arterial Network)

Meidong Huicheng Completes Hundreds of Millions of C++ Round Financing

Recently, Meidong Huicheng Life Science (Kunshan) Co., Ltd. (hereinafter referred to as "Meidong Huicheng") announced the completion of a C++ round of financing worth hundreds of millions of yuan, led by QuDao Asset. The proceeds will be used for the development and operation of consumer healthcare and life science storage pipelines. Meidong Huicheng, which started in Kunshan, Jiangsu in 2017, has successfully achieved large-scale commercialization of its minimally invasive surgical device CDMO business and rapidly expanded its operations to encompass the entire IVD and life science fields. Currently, Meidong Huicheng's product pipeline has extended into the consumer healthcare sector, with the potential to ignite a new growth trajectory. (Source: VbData)

NED+ Successfully Completes Over RMB 100 Million in Series C Financing

Recently, Beijing Ned+ Display Technology Co., Ltd. ("Ned+") completed a C-round financing of over 100 million RMB. This round of financing was successively invested by Hefei Construction Investment and Baohe Venture Capital, as well as the Beijing New Materials Industry Investment Fund. The investors in this round include various top-tier institutions such as primary market players, industrial capital, and government industry funds, forming a cross-perspective capital consensus to accelerate and support the innovation and development of key underlying technologies for the new generation of display optics. (Source: Vbdata.cn)

Xin Hong Life Completes Pre-A+ Round Financing of Tens of Millions of Yuan Led Exclusively by Mingxi Capital

Recently, XinHong Life completed a Pre-A+ round of financing worth tens of millions of RMB, led exclusively by Mingxi Capital. Established in June 2022, XinHong Life is an innovative medical technology company specializing in cardiovascular ultrasound solutions, with a focus on ultrasound energy technology and the integration of pharmaceuticals and devices. The product has now entered the mid-stage of clinical trials. This round of financing will accelerate the industrialization and commercialization of the product, as well as the development of subsequent integrated interventional ultrasound diagnosis and treatment products. (Source: Arterial Network)

Retail Sales of Oral Diabetes Chemical Drugs in Chinese Public Medical Institutions Increased by 7.75% Year-on-Year in the First Half of 2024

Recently, the market for oral diabetes medications has seen renewed activity. Nine new products were approved on the same day, and eight oral diabetes drugs have been included in the new medical insurance list. Data from MiNe Network shows that in the first half of 2024, oral diabetes chemical drugs used in Chinese public medical institutions increased by 7.75% year-on-year. The TOP20 rankings have been reshuffled, with the "top drug" reaching new highs, and Sichuan Weiao Pharmaceutical's Miglitol Tablets breaking into the top ten brands. To date, 63 oral diabetes drug products have passed evaluations, with DeYuan Pharmaceuticals, Qilu Pharmaceuticals, and Zhongda Pharmaceuticals leading the list; the tenth round of bulk procurement for large varieties worth billions is in fierce competition. (Source: MiNe Network)

51 Well-known Chains! Invited by the National Healthcare Security Administration

On December 2, the Office of the National Healthcare Security Administration publicly released an invitation letter for a consultation event on strengthening the application of drug traceability codes in healthcare security supervision. Representatives from 51 pharmaceutical retail enterprises were specifically invited to participate in the consultation at the National Healthcare Security Administration on December 6. Regarding the purpose of this consultation, the Healthcare Security Administration stated that it aims to accelerate the use of drug traceability codes in healthcare supervision, combat the black market of drug resale, rectify illegal activities such as drug swapping, assist companies in preventing product counterfeiting, protect the medication safety and legal rights of insured individuals, support high-quality enterprise development, and contribute to improving the drug traceability management system. (Source: Menet)